Matthias Evers - Evotec SE Chief Board
| EVT Stock | 8.41 0.01 0.12% |
Insider
Matthias Evers is Chief Board of Evotec SE
| Age | 50 |
| Phone | 49 40 560 81 0 |
| Web | https://www.evotec.com |
Evotec SE Management Efficiency
Evotec SE's management efficiency ratios could be used to measure how well Evotec SE manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Andreas Eberhorn | Dermapharm Holding SE | 48 | |
| Christof Dreibholz | Dermapharm Holding SE | 56 | |
| Dirk Toepfer | Merck KGaA | N/A | |
| HansGeorge Feldmeier | Dermapharm Holding SE | N/A | |
| Nikhil Lalwani | ANI Pharmaceuticals | 45 | |
| Gerhard Schmitz | Merck KGaA | 60 | |
| Kai Beckmann | Merck KGaA | 58 | |
| Karin Samusch | Dermapharm Holding SE | N/A | |
| Meredith Cook | ANI Pharmaceuticals | N/A | |
| Belen MD | Merck KGaA | 63 | |
| Christopher Mutz | ANI Pharmaceuticals | 51 | |
| Marcus Kuhnert | Merck KGaA | 55 | |
| Constantin Fest | Merck KGaA | 46 | |
| Friederike Rotsch | Merck KGaA | 51 | |
| Barbara Weiland | Merck KGaA | 49 | |
| Matthias Heinzel | Merck KGaA | 56 | |
| Krista Davis | ANI Pharmaceuticals | N/A | |
| Stephen Carey | ANI Pharmaceuticals | 52 | |
| Chad Gassert | ANI Pharmaceuticals | 47 | |
| Ori Gutwerg | ANI Pharmaceuticals | 49 | |
| Peter Guenter | Merck KGaA | 61 | |
Management Performance
| Return On Equity | -0.16 | |||
| Return On Asset | -0.0012 |
Evotec SE Leadership Team
Elected by the shareholders, the Evotec SE's board of directors comprises two types of representatives: Evotec SE inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Evotec. The board's role is to monitor Evotec SE's management team and ensure that shareholders' interests are well served. Evotec SE's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Evotec SE's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Matthias Evers, Chief Board | ||
| Volker Braun, VP ESG | ||
| Cord Dohrmann, Chief Board | ||
| Enno Spillner, CFO Board | ||
| Monika Conradt, Global HR | ||
| MBA MBA, Chairman CEO | ||
| Christian Dargel, EVP Compliance | ||
| Gabriele Hansen, Sr Marketing | ||
| Craig Johnstone, COO Board | ||
| Anja Bosler, Principal Accounting |
Evotec Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Evotec SE a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.16 | |||
| Return On Asset | -0.0012 | |||
| Profit Margin | (0.26) % | |||
| Operating Margin | (0.01) % | |||
| Current Valuation | 2.54 B | |||
| Shares Outstanding | 176.95 M | |||
| Shares Owned By Insiders | 9.86 % | |||
| Shares Owned By Institutions | 66.45 % | |||
| Price To Book | 2.34 X | |||
| Price To Sales | 3.91 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Evotec Stock Analysis
When running Evotec SE's price analysis, check to measure Evotec SE's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evotec SE is operating at the current time. Most of Evotec SE's value examination focuses on studying past and present price action to predict the probability of Evotec SE's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evotec SE's price. Additionally, you may evaluate how the addition of Evotec SE to your portfolios can decrease your overall portfolio volatility.